Free tool
FAERS Monitor: Inluriyo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218881 or its brand name (Inluriyo, Imlunestrant Tosylate). Reports on generic versions are filed under their own applications.
Reports
92
Serious
25
27% of reports
Hospitalization
8
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea9
- malignant neoplasm progression8
- nausea7
- disease progression6
- fatigue6
- blood creatinine increased4
- decreased appetite4
- hospitalisation4
- malaise4
- pneumonia4
- pruritus4
- anaemia3
- headache3
- hot flush3
- hyponatraemia3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 8 | 17.9 | 9.2 | 112 |
| blood creatinine increasedSignal | 4 | 14.0 | 5.4 | 36 |
| hyponatraemiaSignal | 3 | 12.2 | 4.0 | 21 |
| disease progressionSignal | 6 | 11.6 | 5.3 | 48 |
| hot flushSignal | 3 | 9.1 | 3.0 | 14 |
| hospitalisationSignal | 4 | 6.0 | 2.3 | 12 |
| decreased appetiteSignal | 4 | 3.9 | 1.5 | 6 |
| anaemia | 3 | 3.6 | 1.2 | 3 |
| diarrhoeaSignal | 9 | 3.2 | 1.7 | 12 |
| pneumonia | 4 | 2.8 | 1.1 | 3 |
| pruritus | 4 | 2.4 | 0.9 | 2 |
| malaise | 4 | 2.1 | 0.8 | 1 |
| nausea | 7 | 2.0 | 1.0 | 3 |
| fatigue | 6 | 1.8 | 0.8 | 1 |
| headache | 3 | 1.1 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.